Clinical Study

Nrg-Br004- A Randomized, Double-Blind, Phase III Trial Of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab Or Placebo In First-Line Her2-Positive Metastatic Breast Cancer

Posted Date: Sep 25, 2019

  • Investigator: Neetu Radhakrishnan
  • Specialties: Breast Cancer, Cancer
  • Type of Study: Drug

Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36, and atezolizumab IV /placebo over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab and atezolizumab repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.

Criteria:

Her2 + Metastatic Or Recurrent Breast Cancer, Trial Of Immunotherapy With Std Of Care Antiher 2Neu Therapy

Keywords:

Stage Iv Or Recurrent, Her2/Neu Positive, Immunotherapy

For More Information:

Laura Bundus
51358478476
bundusla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.